Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
Bhattacharya et al.,
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers,
medRxix, doi:10.1101/2020.06.09.20116806 (Preprint)
HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
risk of case, 80.7% lower, RR 0.19, p = 0.001, treatment 4 of 54 (7.4%), control 20 of 52 (38.5%), NNT 3.2.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Bhattacharya et al., 9 Jun 2020, retrospective, India, preprint, 7 authors.
Abstract: International Journal of Research in Medical Sciences
Bhattacharya R et al. Int J Res Med Sci. 2020 Oct;8(10):3518-3522
www.msjonline.org
pISSN 2320-6071 | eISSN 2320-6012
DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20204010
Original Research Article
The beneficial role of N-acetylcysteine as an adjunctive drug in
treatment of COVID-19 patients in a tertiary care hospital in India:
an observational study
Raja Bhattacharya1, Maitry Mondal1, Subhendu Bikash Naiya1, Lamsaka Lyngdoh1,
Rishav Mukherjee1*, Prabhat K. Singh2
1
Department of Medicine, Medical College and Hospital, Kolkata, West Bengal, India
Marwari Relief Society, Kolkata, West Bengal, India
2
Received: 25 August 2020
Revised: 09 September 2020
Accepted: 10 September 2020
*Correspondence:
Dr. Rishav Mukherjee,
E-mail: mukherjeerishav@gmail.com
Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial
use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
Background: N-acetyl cysteine, a mucolytic agent, demonstrates free radical scavenging and anti-inflammatory
properties, and prevents endothelial dysfunction by inhibition of NF-KB and formation of no adducts. This has a
potential role to tackle cytokine storms, endothelial dysfunction and prothrombotic state observed in COVID-19
manifestations like ARDS and Multi organ dysfunction.
Methods: Institution based descriptive cross sectional study, 164 patients from laboratory confirmed RT PCR
positive COVID-19 patients, in the study period from 27th May 2020 to 10th August 2020, were assessed, in medical
college Kolkata, a dedicated COVID-19 care facility.
Results: It was observed that moderate-severe patients who received N-acetyl cysteine along with standard therapy
had average hospital stay duration of 12 days, higher rate of discharge, average duration of oxygen therapy of 8 days,
less number of deaths and reduced transfer to critical care facilities.
Conclusions: N-acetyl cysteine can be considered as an adjunctive therapy with standard protocol driven care, due to
its beneficial anti-inflammatory and free radical scavenging properties.
Keywords: COVID-19, N-acetyl cysteine, Free radical scavenger, Anti-inflammatory
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit